Skip to main content
. 2002 Feb;184(3):849–852. doi: 10.1128/JB.184.3.849-852.2002

FIG. 1.

FIG. 1.

(A) Western blot analysis of B. mallei ATCC 23344. Proteinase K-treated whole-cell lysates were used. In lane 1, the primary antibody used was a 1/2,000 dilution of polyclonal antisera raised against a B. pseudomallei BSA-O-PS conjugate, and in lane 2, the primary antibody used was a 1/2,000 dilution of the B. pseudomallei O-PS-specific MAb (Pp-PS-W). (B) Western blot profiles of proteinase K-treated whole-cell lysates of B. mallei strains. The primary antibody used was polyclonal sera raised against a B. pseudomallei BSA-O-PS conjugate. Lanes: 1, NCTC 120; 2, NCTC 10248; 3, NCTC 10229; 4, NCTC 10260; 5, NCTC 10247; 6, ATCC 23344; 7, NCTC 3708; 8, NCTC 3709; 9, ATCC 10399; and 10, ATCC 15310. (C) Silver stain analysis of proteinase K-treated whole-cell lysates of B. mallei strains. Lanes: 1, NCTC 120; 2, NCTC 10248; 3, NCTC 10229; 4, NCTC 10260; 5, NCTC 10247; 6, ATCC 23344; 7, NCTC 3708; 8, NCTC 3709; 9, ATCC 10399; and 10, ATCC 15310.